HRP20211845T1 - Derivati bipirazolila korisni za liječenje autoimunih bolesti - Google Patents
Derivati bipirazolila korisni za liječenje autoimunih bolesti Download PDFInfo
- Publication number
- HRP20211845T1 HRP20211845T1 HRP20211845TT HRP20211845T HRP20211845T1 HR P20211845 T1 HRP20211845 T1 HR P20211845T1 HR P20211845T T HRP20211845T T HR P20211845TT HR P20211845 T HRP20211845 T HR P20211845T HR P20211845 T1 HRP20211845 T1 HR P20211845T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- formula
- pharmaceutically acceptable
- hydrate
- acceptable salt
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 34
- 150000003839 salts Chemical class 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 claims 3
- 230000008878 coupling Effects 0.000 claims 3
- 238000010168 coupling process Methods 0.000 claims 3
- 238000005859 coupling reaction Methods 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 125000004970 halomethyl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Claims (23)
1. Spoj, naznačen time, da je predstavljen formulom (I)
[image]
u kojoj:
Cy se bira od
[image]
ili
[image]
;
svaki R1 se neovisno bira od vodika ili metila;
R2 je L-Ar, pri čemu Ar je fenil ili piridinil i svaki je opcionalno supstituiran s jednim ili više od sljedećih: halogen, halo C1-4 alkil, C1-4 alkil, C1-4 alkoksi, -CN, halo C1-4 alkoksi, ili cikloalkil;
L je -(CH2)- ili -(CHCH3)-;
Y je C6-C8 spirocikl koji sadrži jedan atom dušikovog prstena, i supstituiran je s jednim R3;
R3se bira od
[image]
, ili
[image]
;
svaki R4 se neovisno bira od vodika, C1-4 alkila, ili C3-4 cikloalkila;
svaka skupina koja je gore definirana za R1-R4 i Y, može biti djelomično ili potpuno halogenirana, tamo gdje je to moguće;
ili njegova farmaceutski prihvatljiva sol ili hidrat.
2. Spoj prema patentnom zahtjevu 1, naznačen time, da
Y se bira od
[image]
ili
[image]
;
ili njegova farmaceutski prihvatljiva sol ili hidrat.
3. Spoj prema patentnom zahtjevu 1, naznačen time, da
Cy jest
[image]
Y se bira od
[image]
ili
[image]
;
pri čemu R3je
[image]
, ili
[image]
;
svaki R4 se neovisno bira od vodika, C1-4 alkila, ili C3-4 cikloalkila;
ili njegova farmaceutski prihvatljiva sol ili hidrat.
4. Spoj prema patentnom zahtjevu 1, naznačen time, da
Cy jest
[image]
Y se bira od
[image]
;
pri čemu R3jest
[image]
;
R4 se bira od vodika, C1-4 alkila, ili C3-4 cikloalkila;
ili njegova farmaceutski prihvatljiva sol ili hidrat.
5. Spoj prema patentnom zahtjevu 1, naznačen time, da
Cy jest
[image]
Y se bira od
[image]
;
pri čemu R3 jest
[image]
;
R4 se bira od vodika, C1-4 alkila, ili C3-4 cikloalkila;
ili njegova farmaceutski prihvatljiva sol ili hidrat.
6. Spoj prema patentnom zahtjevu 1, naznačen time, da
Cy jest
[image]
Y se bira od
[image]
;
pri čemu R3 jest
[image]
;
svaki R4 se neovisno bira od vodika, C1-4 alkila, ili C3-4 cikloalkila;
ili njegova farmaceutski prihvatljiva sol ili hidrat.
7. Spoj prema patentnom zahtjevu 1, naznačen time, da
Cy jest
[image]
Y se bira od
[image]
;
pri čemu R3 jest
[image]
;
svaki R4 se neovisno bira od vodika, C1-4 alkila, ili C3-4 cikloalkila;
ili njegova farmaceutski prihvatljiva sol ili hidrat.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, da
se svaki R4 neovisno bira od vodika, metila, ili ciklopropila;
ili njegova farmaceutski prihvatljiva sol ili hidrat.
9. Spoj prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time, da
R2 je L-Ar, pri čemu Ar je fenil ili piridinil i svaki je opcionalno supstituiran s jednim ili više od sljedećih: halogen, halometil, metil, metoksi, -CN, halometoksi, ili ciklopropil;
L je -(CH2)- ili -(CHCH3)-;
ili njegova farmaceutski prihvatljiva sol ili hidrat.
10. Spoj, naznačen time, da se bira od:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
ili njihove farmaceutski prihvatljive soli ili hidrati.
11. Spoj prema patentnom zahtjevu 1, naznačen time, da je predstavljen formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili hidrat.
12. Spoj prema patentnom zahtjevu 1, naznačen time, da je predstavljen formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili hidrat.
13. Spoj prema patentnom zahtjevu 1, naznačen time, da je predstavljen formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili hidrat.
14. Spoj prema patentnom zahtjevu 1, naznačen time, da je predstavljen formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili hidrat.
15. Spoj prema patentnom zahtjevu 1, naznačen time, da je predstavljen formulom:
[image]
16. Spoj prema patentnom zahtjevu 1, naznačen time, da je predstavljen formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili hidrat.
17. Spoj prema patentnom zahtjevu 1, naznačen time, da je predstavljen formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili hidrat.
18. Spoj prema patentnom zahtjevu 1, naznačen time, da je predstavljen formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili hidrat.
19. Spoj prema patentnom zahtjevu 1, naznačen time, da je predstavljen formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili hidrat.
20. Spoj prema patentnom zahtjevu 1, naznačen time, da je predstavljen formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili hidrat.
21. Farmaceutski pripravak, naznačen time, da sadrži terapijski učinkovitu količinu spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 17, ili njegove farmaceutski prihvatljive soli ili hidrata.
22. Spoj prema bilo kojem od patentnih zahtjeva 1 do 20, ili njegova farmaceutski prihvatljiva sol ili hidrat, naznačen time, da je za uporabu u liječenju bolesti odabrane od reumatoidnog artritisa, sustavnog eritematoznog lupusa, lupus nefritisa, Sjögrenove bolesti, vaskulitisa, skleroderme, astme, alergijskog rinitisa, alergijskog ekcema, limfoma B stanica, multiple skleroze, mladenačkog reumatoidnog artritisa, mladenačkog idiopatskog artritisa, upalne bolesti crijeva, bolesti - usadak protiv domaćina, psorijatičkog artritisa, ankiloznog spondilitisa i uveitisa.
23. Postupak priprave spoja prema patentnom zahtjevu 1, naznačen time, da obuhvaća:
(i) spajanje spoja formule A
[image]
sa spojem formule E
[image]
za tvorbu spoja formule G
[image]
pri čemu se svaki R1 neovisno bira od vodika ili metila; X je halogen; LG je izlazna skupina; i Y’ je C6-C8 spirocikl koji sadrži jedan dušikov prsten pokriven zaštitnom skupinom;
(ii) spajanje spoja formula (I-1) s heterocikličkim bornim esterom ili kiselinom formule C
[image]
u prisutnosti prikladne baze i paladijevog katalizatora dok nakon toga slijedi hidroliza nitrila u karboksamid za tvorbu spoja formule (II-1)
[image]
pri čemu svaka R skupina spoja formule C je H, alkil, ili su obje R skupine povezane za tvorbu prstena;
Cy se u spoju formule (II-1) bira od
[image]
ili
[image]
;
R2 je L-Ar, pri čemu Ar je fenil ili piridinil i svaki je opcionalno supstituiran s jednim ili više od sljedećih: halogen, halo C1-4 alkil, C1-4 alkil, C1-4 alkoksi, -CN, halo C1-4 alkoksi, ili cikloalkil;
L je -(CH2)- ili -(CHCH3)-; i
(iii) uklanjanje zaštite pokrivenog dušika spoja formule (II-1) pod kiselim uvjetima i spajanje nezaštićenog spoja formule (II-1) sa spojem koji se bira od
[image]
ili
[image]
za tvorbu spoja formule (I)
[image]
pri čemu Y je C6-C8 spirocikl koji sadrži jedan dušikov prsten vezan s R3, pri čemu
R3 je
[image]
, ili
[image]
;
svaki R4 se neovisno bira od vodika, C1-4 alkila, ili C3-4 cikloalkila;
ili njegove farmaceutski prihvatljive soli.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562268278P | 2015-12-16 | 2015-12-16 | |
| US201662431008P | 2016-12-07 | 2016-12-07 | |
| PCT/US2016/066799 WO2017106429A2 (en) | 2015-12-16 | 2016-12-15 | Heteroaromatic compounds as btk inhibitors |
| EP16867378.8A EP3390390B1 (en) | 2015-12-16 | 2016-12-15 | Bipyrazolyl derivatives useful for the treatment of autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211845T1 true HRP20211845T1 (hr) | 2022-03-04 |
Family
ID=58737849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211845TT HRP20211845T1 (hr) | 2015-12-16 | 2016-12-15 | Derivati bipirazolila korisni za liječenje autoimunih bolesti |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US9975882B2 (hr) |
| EP (1) | EP3390390B1 (hr) |
| JP (1) | JP6976947B2 (hr) |
| KR (1) | KR20180095655A (hr) |
| CN (1) | CN108368086B (hr) |
| AU (1) | AU2016370743B2 (hr) |
| BR (1) | BR112018011969B1 (hr) |
| CA (1) | CA3005268C (hr) |
| CL (1) | CL2018001569A1 (hr) |
| CO (1) | CO2018005954A2 (hr) |
| CY (1) | CY1124749T1 (hr) |
| DK (1) | DK3390390T3 (hr) |
| EA (1) | EA034561B1 (hr) |
| ES (1) | ES2897910T3 (hr) |
| HK (1) | HK1256795A1 (hr) |
| HR (1) | HRP20211845T1 (hr) |
| HU (1) | HUE056877T2 (hr) |
| IL (1) | IL259281B (hr) |
| LT (1) | LT3390390T (hr) |
| MX (1) | MX2018007333A (hr) |
| MY (1) | MY197440A (hr) |
| PE (1) | PE20181074A1 (hr) |
| PH (1) | PH12018501248A1 (hr) |
| PL (1) | PL3390390T3 (hr) |
| PT (1) | PT3390390T (hr) |
| RS (1) | RS62525B1 (hr) |
| SA (1) | SA518391864B1 (hr) |
| SG (1) | SG11201804890TA (hr) |
| SI (1) | SI3390390T1 (hr) |
| TW (1) | TWI726017B (hr) |
| WO (1) | WO2017106429A2 (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2882741B1 (en) | 2012-08-10 | 2018-10-24 | Boehringer Ingelheim International GmbH | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| PL3390390T3 (pl) * | 2015-12-16 | 2022-01-24 | Boehringer Ingelheim International Gmbh | Pochodne bipirazolilu przydatne w leczeniu chorób autoimmunologicznych |
| EP3390395B1 (en) | 2015-12-16 | 2020-09-09 | Loxo Oncology, Inc. | Compounds useful as kinase inhibitors |
| JP6916185B2 (ja) | 2016-01-13 | 2021-08-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｔｋ阻害剤としてのイソキノロン類 |
| EP3661939B1 (en) * | 2017-08-01 | 2021-07-21 | Boehringer Ingelheim International GmbH | Intermediate compounds and methods |
| CA3108065A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| JP2022533968A (ja) * | 2019-05-23 | 2022-07-27 | ノバルティス アーゲー | ブルトン型チロシンキナーゼ阻害剤を使用したシェーグレン症候群を処置する方法 |
| WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| WO2023110970A1 (en) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Macrocyclic btk inhibitors |
| WO2023110936A1 (en) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Reversible macrocyclic kinase inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9608435D0 (en) | 1996-04-24 | 1996-06-26 | Celltech Therapeutics Ltd | Chemical compounds |
| AU782878B2 (en) * | 2000-02-05 | 2005-09-08 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
| EA007933B1 (ru) | 2001-08-13 | 2007-02-27 | Янссен Фармацевтика Н.В. | 2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность |
| US7307097B2 (en) | 2001-09-27 | 2007-12-11 | Smithkline Beechman Corporation | Chemical compounds |
| FR2881426B1 (fr) | 2005-02-03 | 2007-03-30 | Aventis Pharma Sa | Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation |
| EP2007732B1 (en) | 2006-04-11 | 2011-11-23 | Vertex Pharmaceuticals, Inc. | Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases |
| KR101315610B1 (ko) | 2006-09-22 | 2013-10-10 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제 억제제 |
| CA2874756C (en) | 2007-03-28 | 2018-05-29 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| DK2310528T3 (da) | 2008-07-29 | 2013-12-02 | Univ Liege | Genetisk markør-test til brachyspina og frugtbarhed hos kvæg |
| GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
| CN102395585A (zh) | 2009-01-30 | 2012-03-28 | 米伦纽姆医药公司 | 杂芳基化合物和其作为pi3k抑制剂的用途 |
| WO2011082732A1 (de) | 2009-12-17 | 2011-07-14 | Merck Patent Gmbh | Inhibitoren der sphingosinkinase |
| EP2578585B1 (en) | 2010-05-31 | 2016-07-20 | ONO Pharmaceutical Co., Ltd. | Purinone derivative as btk kinase inhibitor |
| WO2012021615A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| EP2809673B1 (en) * | 2012-01-31 | 2016-11-02 | Nanjing Allgen Pharma Co. Ltd. | Spirocyclic molecules as bruton's tyrosine kinase inhibitors |
| EP2882741B1 (en) | 2012-08-10 | 2018-10-24 | Boehringer Ingelheim International GmbH | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| US20150291554A1 (en) | 2012-11-02 | 2015-10-15 | Pfizer Inc. | Bruton's Tyrosine Kinase Inhibitors |
| CN103848810A (zh) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
| EP2970163B1 (en) * | 2013-03-14 | 2018-02-28 | Boehringer Ingelheim International GmbH | 5-thiazolecarboxamide dervatives and their use as btk inhibitors |
| WO2015116485A1 (en) * | 2014-01-29 | 2015-08-06 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as btk inhibitors |
| PL3390390T3 (pl) * | 2015-12-16 | 2022-01-24 | Boehringer Ingelheim International Gmbh | Pochodne bipirazolilu przydatne w leczeniu chorób autoimmunologicznych |
-
2016
- 2016-12-15 PL PL16867378T patent/PL3390390T3/pl unknown
- 2016-12-15 JP JP2018531127A patent/JP6976947B2/ja active Active
- 2016-12-15 CA CA3005268A patent/CA3005268C/en active Active
- 2016-12-15 HR HRP20211845TT patent/HRP20211845T1/hr unknown
- 2016-12-15 DK DK16867378.8T patent/DK3390390T3/da active
- 2016-12-15 WO PCT/US2016/066799 patent/WO2017106429A2/en active Application Filing
- 2016-12-15 PT PT168673788T patent/PT3390390T/pt unknown
- 2016-12-15 LT LTEPPCT/US2016/066799T patent/LT3390390T/lt unknown
- 2016-12-15 BR BR112018011969-5A patent/BR112018011969B1/pt active IP Right Grant
- 2016-12-15 MX MX2018007333A patent/MX2018007333A/es active IP Right Grant
- 2016-12-15 US US15/379,745 patent/US9975882B2/en active Active
- 2016-12-15 SG SG11201804890TA patent/SG11201804890TA/en unknown
- 2016-12-15 KR KR1020187020450A patent/KR20180095655A/ko active IP Right Grant
- 2016-12-15 RS RS20211356A patent/RS62525B1/sr unknown
- 2016-12-15 MY MYPI2018000892A patent/MY197440A/en unknown
- 2016-12-15 HU HUE16867378A patent/HUE056877T2/hu unknown
- 2016-12-15 EA EA201891399A patent/EA034561B1/ru not_active IP Right Cessation
- 2016-12-15 PE PE2018001111A patent/PE20181074A1/es unknown
- 2016-12-15 EP EP16867378.8A patent/EP3390390B1/en active Active
- 2016-12-15 AU AU2016370743A patent/AU2016370743B2/en active Active
- 2016-12-15 ES ES16867378T patent/ES2897910T3/es active Active
- 2016-12-15 TW TW105141510A patent/TWI726017B/zh active
- 2016-12-15 SI SI201631382T patent/SI3390390T1/sl unknown
- 2016-12-15 CN CN201680072250.3A patent/CN108368086B/zh active Active
-
2017
- 2017-10-12 US US15/782,214 patent/US20180030037A1/en not_active Abandoned
-
2018
- 2018-04-09 US US15/947,978 patent/US20180222893A1/en not_active Abandoned
- 2018-05-10 IL IL259281A patent/IL259281B/en active IP Right Grant
- 2018-06-12 CO CONC2018/0005954A patent/CO2018005954A2/es unknown
- 2018-06-13 PH PH12018501248A patent/PH12018501248A1/en unknown
- 2018-06-13 CL CL2018001569A patent/CL2018001569A1/es unknown
- 2018-06-23 SA SA518391864A patent/SA518391864B1/ar unknown
- 2018-09-21 US US16/137,790 patent/US20190092759A1/en not_active Abandoned
- 2018-12-11 HK HK18115878.5A patent/HK1256795A1/zh unknown
-
2019
- 2019-08-29 US US16/555,205 patent/US20200055843A1/en not_active Abandoned
-
2020
- 2020-07-23 US US16/936,821 patent/US20210009567A1/en not_active Abandoned
-
2021
- 2021-11-24 CY CY20211101015T patent/CY1124749T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211845T1 (hr) | Derivati bipirazolila korisni za liječenje autoimunih bolesti | |
| ES2750236T3 (es) | Derivados heteroaromáticos bicíclicos condensados como moduladores de la actividad del TNF | |
| ES2775535T3 (es) | Derivados de benzotriazol como moduladores de la actividad del TNF | |
| ES2743208T3 (es) | Derivados de tetrahidroimidazopiridina como moduladores de la actividad TNF | |
| ES2732156T3 (es) | Derivados de pirazolopiridina como moduladores de la actividad de TNF | |
| ES2809530T3 (es) | Derivados de imidazotriazina como moduladores de la actividad de TNF | |
| ES2817051T3 (es) | Derivados de imidazopirimidina como moduladores de la actividad de TNF | |
| ES2809533T3 (es) | Derivados de imidazopiridina como moduladores de la actividad de TNF | |
| HRP20230090T1 (hr) | Heterociklički spojevi kao imunomodulatori | |
| ES2759253T3 (es) | Derivados de imidazol tricíclicos condensados como moduladores de la actividad de TNF | |
| ES2810774T3 (es) | Derivados de imidazopiridina como moduladores de la actividad de TNF | |
| ES2809535T3 (es) | Derivados de imidazopiridina como moduladores de la actividad de TNF | |
| ES2730942T3 (es) | Derivados de triazolopiridina como moduladores de la actividad de TNF | |
| AU2006301708B2 (en) | Glycyrrhetinic acid-30-amide derivatives and the uses thereof | |
| ES2809536T3 (es) | Derivados de imidazopiridina como moduladores de la actividad de TNF | |
| HRP20090673T1 (hr) | Derivati kvinolina i njihova uporaba kao mikobakterijskih inhibitora | |
| JP2012521406A5 (hr) | ||
| HRP20160396T1 (hr) | Novi kiralni n-acil-5,6,7(8-susupstituirani)-tetrahidro-/1,2,4/triazolo/4,3-a/pirazini kao selektivni nk-3 receptor antagonisti, farmaceutski pripravak, i metode za upor | |
| JP2016515562A5 (hr) | ||
| RU2006127455A (ru) | Новые производные пиридина, способ их получения и содержащая их фармацевтическая композиция | |
| HRP20120830T1 (hr) | Imidazolkarboksamidi | |
| ES2743190T3 (es) | Derivados de imidazotizol como moduladores de la actividad de TNF | |
| AR063680A1 (es) | Derivados de pirazolo[1, 5-a]pirimidina, metodos e intermediario para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion de mglur5. | |
| WO2007054770A3 (en) | Pyrazole derivatives and their medical use | |
| CA2931581A1 (en) | Purine derivatives as modulators of tnf activity |